600196 复星医药
2024/06 - 中期
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额1,907,0043,414,2174,217,5713,937,8152,579,774
投资活动产生之现金流量净额(2,649,949)(3,819,290)(4,064,038)(3,857,489)(4,706,229)
筹资活动产生之现金流量净额1,090,564(1,336,250)4,428,475(819,407)1,467,129
汇率变动对现金及现金等价物的影响17,13173,645128,342(134,712)(300,165)
现金及现金等价物净增加/(减少)364,751(1,667,678)4,710,350(873,794)(959,490)
期初现金及现金等价物余额9,502,38911,170,0676,459,7177,333,5118,284,371
期末现金及现金等价物余额9,867,1409,502,38911,170,0676,459,7177,324,881